vaayaa.com
Healthcare 1 min read

FDA Approves Drug to Treat Neurologic Manifestations of Hunter Syndrome

Apr 25, 2026

The U.S. Food and Drug Administration approved Avlayah (tividenofusp alfa-eknm) to treat certain individuals with Hunter syndrome (Mucopolysaccharidosis type II or MPS II).

Read full article on FDA Press Releases →

Source: FDA Press Releases — US Government, Public Domain

More in Healthcare

Dads today talk more freely with their teens about sex and relationships The Conversation Health · 2 min How cuts to CDC are dismantling its capacity to protect Americans’ health The Conversation Health · 2 min FDA Issues Draft Guidance to Help Accelerate Cell and Gene Therapies for Patients FDA Press Releases · 1 min FDA Expands Sunscreen Options for the First Time in 20 Years FDA Press Releases · 1 min